The type of platinum found in the women's blood and urine was different than the traces of regular platinum not uncommon in people's bodies. It was a highly reactive platinum, used to help turn silicon oil into the honey-like gel that lends a more natural feel to a breast implant.

Concentrations were up to three times higher than in women who didn't have breast implants, according to findings by S.V.M. Maharaj, a chemist at American University. Maharaj was scheduled present the findings Thursday to the American Chemical Society in Philadelphia.

Ernest Lykissa, a forensic - http://realitysandwich.com/?s=forensic and 구리출장안마 - https://www.softanma.com/18-guli clinical toxicologist who co-authored the paper, said the study's sample size was small. But Lykissa said it fairly represented hundreds of women with implants he's studied over the years.

Women who had implants the longest recorded the highest platinum concentrations. The heavy metal was also found in bone marrow, where blood cells are made.

Distinct from platinum released by catalytic converters in cars, platinum in implants is treated with nitric and hydrochloric acids and becomes very reactive, Lykissa said. The heavy metal readily binds in the human body, especially to nerve endings, short-circuiting communication with the brain.

"You see green, but you perceive a full moon," he said. "All of a sudden, your brain system is not working right."

Some women developed nervous tics, had faulty perception, and impaired hearing and eyesight, he said.

Children born to women with implants had problems with eyesight and hearing, too, but those nervous system disorders may have been caused by something else, he cautioned.

The Food and Drug Administration in January stunned plastic surgeons when, contradicting the advice of its expert panel, it rejected Inamed's bid to reintroduce silicone breast implants. After safety concerns rose, the FDA banned such implants in 1992 for most patients.

In January, the drug regulatory agency asked Inamed for more details about what happens when silicone seeps from the implant.

Dan Cohen, a spokesman for Santa Barbara, Calif.-based Inamed, said the company would speak in detail about its formal reply, submitted to the FDA earlier this month.

But at the FDA's October 2003 advisory board - http://www.zixiutangpollencapsules.com/?s=advisory%20board meeting, the company briefly discussed platinum dispersion and concentration in implant patients. The company has tracked those patients for three years.

"It was not an issue that anyone dwelled on — either our presentation or the panel," Cohen said.

For its part, the FDA in 2002 surveyed scientific literature that indicated platinum leaks from implants into surrounding breast tissue. Researchers said they didn't find anything suggesting women had allergic responses to leached platinum.

Paul H. Wooley, director of research for orthopedic surgery at Wayne State University, said it's been suspected for at least a decade that heavy metals used in manufacturing might cause problems for women who receive implants.

"I'm not sure these questions have been answered because, in general, they haven't been asked," Wooley said. "For political reasons, working on breast-implant patients has been somewhat difficult to do."

By Diedtra Henderson

CAIRO -- Yemen's warring parties will meet in Sweden this week for another attempt at talks aimed at halting their catastrophic 3-year-old war, but there are few incentives for major compromises, and the focus is likely to be on firming up a shaky de-escalation.

U.N. officials say they don't expect rapid progress toward a political settlement but hope for at least minor steps that would help to address Yemen's worsening humanitarian crisis.

Both the internationally-recognized government, which is backed by a U.S.-sponsored and Saudi-led coalition, and the Iran-aligned Houthi rebels say they are striving for peace. A Houthi delegation arrived in Stockholm late Tuesday, accompanied by U.N. envoy Martin Griffiths. The government delegation and the head of the rebel delegation were heading to Sweden on Wednesday.

More in Yemen's Civil War

Confidence-building measures before the talks included a prisoner swap and the evacuation of wounded rebels for medical treatment. The release of funds from abroad by Yemeni President Abed Rabbo Mansour Hadi to pay state employees in rebel-held territory is also in the works.

Yemeni scholar Hisham Al-Omeisy, who has written extensively about the conflict, said the talks would focus on "de-escalation and starting the political process."

"It's not much, but given the humanitarian situation and toxic political atmosphere currently prevalent in Yemen, it's better than nothing."

The conflict began with the Houthi takeover of the capital, Sanaa, and much of northern Yemen in 2014. The Saudi-led coalition went to war with the rebels the following March.

The war has claimed at least 10,000 lives, with experts estimating a much higher toll. Saudi-led airstrikes have hit schools, hospitals and wedding parties, and the Houthis have fired long-range missiles into Saudi Arabia and targeted vessels in the Red Sea.

The fighting in Yemen has generated the world's worst humanitarian crisis. The executive director of the U.N.'s World Food Program, David Beasley, said Tuesday that 12 million people suffer from "severe hunger."

"I've heard many say that this is a country on the brink of catastrophe," Beasley said. "This is not a country on the brink of a catastrophe. This is a country that is in a catastrophe."

The mounting humanitarian needs, and outrage over the killing of Saudi writer Jamal Khashoggi, have galvanized international support for ending the war. The United States has called for a cease-fire and reduced some of its logistical aid for the coalition. Iran has also signaled support, urging all sides "to have constructive and responsible participation in the talks."

But previous peace efforts have failed, with neither side willing to compromise.

Saudi Arabia is unlikely to tolerate what it views as an Iranian proxy on its doorstep, and the Houthis have little incentive to withdraw from the capital and other territories they have captured and 전주출장마사지 - https://www.anmapop.com/%ec%a0%84%ec%a3%bc%ec%b6%9c%ec%9e%a5%ec%83%b5%cf... held at great cost. Other armed groups taking part in the chaotic civil war, including southern separatists and local militias, will not be taking part in this week's talks.

At the same time, the two main parties could see the other as weakened, tempting them to make maximalist demands. Saudi Arabia has come under heavy U.S. pressure since the killing of Khashoggi, and the Houthis are under intense financial strain.

The impasse is on vivid display in Hodeida, a Red Sea port city - http://ms-jd.org/search/results/search&keywords=port%20city/ where Yemen imports 70 percent of its food and humanitarian aid. Forces backed by Saudi Arabia and the United Arab Emirates have been trying to capture the city for months, but have been held off by rebels dug in on its outskirts, with neither side willing to back down.

The fighting in and around Hodeida killed nearly 1,500 civilians last month alone, and has displaced at least 134,000 families since June, according to the U.N. office for humanitarian aid.

In an appeal from Yemen, the regional director of the U.N. agency for children called for an immediate end to the years-long war.

"Yemen today is a living hell for millions of children ... there is only one massage to those who are gathering today in Sweden. That is the message of peace for this brutal war ... for that war to stop now," said UNICEF's Geert Cappelaere.

One idea likely to be discussed at the talks is a proposal for the rebels to hand over Hodeida to some type of U.N. administration. The two sides might also discuss further prisoner releases.

But the Houthis are unlikely to agree to withdraw from territory or lay down their arms, as the Yemeni government has repeatedly demanded. And Hadi's administration is unlikely to agree to a power-sharing arrangement that would grant the Houthis a larger role in government, which was one of the original aims of the rebellion.

"I don't expect much from this round," said Baligh al-Makhlafy, a Yemeni pro-government analyst attending the talks as a technical consultant. "Maybe there'll be some more exchange of prisoners or some progress on the economy, but I don't think the Houthis will leave Hodeida peacefully. They believe they have a powerful card there."

The company said it will hold up shipment of about 50 million shots — about half the supply U.S. health officials had hoped to have on hand this year — while it investigates what went wrong and 파주출장안마 - https://www.softanma.com/25-paju determines whether the vaccine is safe to use.

U.S. health officials said some people may not get flu shots when they want this year, but that they were hopeful Chiron's - http://edublogs.org/?s=hopeful%20Chiron%27s production problems are only temporary. Demand typically peaks in October and November.

"Based on what we know, we don't expect a major delay and we believe we can effectively vaccinate the population at risk," CDC director Dr. Julie Gerberding said. "We are in daily contact with Chiron and we will be tracking this along with the Food and Drug Administration."

Flu kills 36,000 people and hospitalizes another 114,000 in an average year, primarily the elderly, according to the CDC.

Last year's flu season got off to an unusually early and harsh start, which raised fears and caused demand for vaccines to outstrip supply for the first time.

Health officials expect a record number of people to request vaccinations this year owing to the publicity generated by last year's season and the subsequent shortage. The CDC ordered 100 million doses to be made for this season, about 17 million more doses than last year.

Chiron supplies about half the nation's flu vaccine. Aventis Pasteur supplies most of the rest.

Chiron officials Thursday said the company now hopes to ship between 46 million and 48 million doses by early October, about a month later than usual.

"There's no product that is going to go into the arms of the American public that will not have been deemed to have met the highest standards of safety," Chiron chief executive Howard - https://www.biggerpockets.com/search?utf8=%E2%9C%93&term=executive%20Howard Pien said.

He said about 1 million doses have already been shipped, but no vaccines have yet reached the public.

Emeryville-based Chiron would not give details on the nature of the contamination, which Pien said was found in a small number of batches at the company's factory in Liverpool, England.

Last year, the company made 38 million shots, accounting for about $230 million in revenue.

Because of the production problems, Chiron also warned that its earnings will meet the "low end" of a forecast range of $1.50 to $1.60. The company made the announcement after the stock markets closed. In after hours trading, the company's stock plunged nearly 7 percent, or $3.24.

(c)MMIV, The Associated Press. All Rights Reserved. This material may not be published, broadcast, rewritten, or redistributed

아산출장마사지 - https://www.startopanma.com/%ec%95%84%ec%82%b0%ec%98%a4%ed%94%bc%ea%b1%b...

Our new digital series "In The Life Of:" follows creative individuals that work behind the scenes to bring you some of your favorite films, theater productions, art and music. In our first episode we follow Broadway director and choreographer Steven Hoggett two weeks away from an opening night workshop production entitled "We Are Here," based on the '70s disco scene in New York City, using the music of legendary composer and producer Nile Rodgers.

You may already be a fan of Steven Hoggett's work and 양구출장안마 - https://www.opanma.com/16-yanggu not even know it. The British director and choreographer has worked on such Broadway productions as Green Day's "American Idiot," "Peter and the Starcatcher" (which won him the 2011 Lucille Lortel Award for Outstanding Choreographer), and most recently "Harry Potter and the Cursed Child," for which he was nominated for a Tony for Best Choreography.

His newest venture is a collaboration with legendary record producer, songwriter and musician Nile Rodgers, of Chic fame. Multiple Grammy-winner Rodgers has collaborated with some of the biggest stars in music, including Donna Summer, David Bowie, Madonna and Diana Ross.

"We Are Here" is a new show in development that will plunge audiences into the hedonistic world of disco. Hoggett directs and Rodgers has dug deep into his timeless music archives to deliver a new show that experiments with the use of music, video, movement and storytelling within an exciting, high-energy performance environment inside the NYC's famed East Village theater space at La MaMa (dubbed "The GlitterLoft" for the show's short run).

New York City 1970s. Behind the velvet rope, people of every race, class and sexual identity come together, encouraged to wear whatever they want, kiss whoever they want and, of course, dance however they want. "We Are Here" highlights the music bedrock of disco's iconic tracks - http://www.buzzfeed.com/search?q=iconic%20tracks to explore the rise of a popular movement, and the stunning backlash against it. Forget white suits and mirror balls – this is a celebration of the beat that set the world on fire, and continues to unify generations and cultures at a time when it is needed more than ever.

Hoggett couldn't agree more. "The minute you start to look at disco beyond the immediate sheen of it, it's really fascinating," he said. "It's an incredible part of New York history and the early '70s. And then Nile, really if you just start to list everything he did in those years, but also the minute you step outside that you look at all his production credits and writing credits, yeah you just start to really track this beautiful journey through music.

"I always liked the idea of music having that kind of, just different streams of influence just flying over each other and everywhere else. It's nice to really show what Nile did and thought and said – and what he produced and how he produced it, and how he stayed true but was developing, pioneering at the same time. So, that's been a real joy."

Not to mention having an excuse to "put your headphones on and listen to disco."

Written by Olivier Award-winner Michael Wynne ("The Priory"), "We Are Here" immerses audiences in mind-blowing video images created by projection designer Darrel Maloney, whose Broadway credits include "American Idiot," "The Illusionists," and "On Your Feet," with lighting design by Olivier Award-winner Natasha Chivers ("Sunday in the Park With George"), and sound design by Olivier Award-winner Tom Gibbons. The choreographer is Yasmine Lee, who has worked as Hoggett's associate movement director on "Harry Potter and the Cursed Child," "The Curious Incident of the Dog in The Night-Time," "The Crucible" and "Once." Set and costumes are designed by Tony Award-winner David Zinn, whose Broadway credits include "SpongeBob SquarePants," "Fun Home" and "The Humans."

"We Are Here," which is produced by Spiegelworld and Showcase Performances, runs July 31 through August 4 at The GlitterLoft, New York City.

The pharmacies accuse the 15 drug makers of illegally conspiring to charge inflated prices in the United States while barring pharmacies from buying the makers' drugs at lower prices outside the country.

"Each of the companies, all of them, are doing exactly the same thing: They're charging substantially more in the United States than they are elsewhere," Joseph Alioto, the San Francisco attorney representing the pharmacies, told KCBS Radio's Matt Bigler. "Almost all of the countries of the world are in one price range and the United States is 300 to 400 times greater."

Alioto filed the suit in Alameda County Superior Court in Oakland. The suit alleges the pharmaceutical companies have hurt the pharmacies' bottom lines by violating California's antitrust and unfair business practices laws.

"While Pfizer hasn't had an opportunity to review this lawsuit in detail, any allegations of price fixing are totally without merit," said Bryant Haskins, a spokesman for New York-based Pfizer Inc., which is named in the lawsuit. "Importation of pharmaceutical products into the U.S. market is both illegal and dangerous because it increases the opportunity to introduce counterfeit or unapproved drugs into the distribution system."

The California lawsuit comes at a time when pharmaceutical companies are coming under increased scrutiny over their drug costs and marketing practices. Many of the same drugs sold in the United States are available in Canada and elsewhere for fractions of the retail prices.

"I get people that are going online and checking prices and saying 'Wow, I can buy this drug up in Canada for a third of the price you're charging me here,' and I don't have anything to respond other than the fact that I say, 'Jeez, you better go do it,'" said San Francisco pharmacist John Gelinas.

The Food and Drug Administration has repeatedly - https://www.biggerpockets.com/search?utf8=%E2%9C%93&term=repeatedly denied requests to import drugs from Canada, where the government controls prices and drugs are less expensive. It says that would open the door, through Canada, to drugs from other countries where quality control isn't as stringent as in the U.S.

Alioto says there's an overall conspiracy to create an artificial trade barrier around the U.S.

"The smoking gun obviously is very obvious, and that is the extreme price differential on the same drug," he told KCBS-AM.

The state of Vermont has filed a lawsuit against the federal agency over the issue.

Last month, Schering-Plough Corp. agreed to pay $346 million to settle charges that it paid a kickback to a health insurer in an attempt to evade a law requiring it to give its lowest prices to Medicaid, the government health program for the poor. Bayer has paid $257 million and GlaxoSmithKline has paid $86.7 million to settle similar allegations that they failed to give their best prices to Medicaid.

Other companies named in the lawsuit include Merck, Johnson & Johnson, 나주출장마사지 - https://www.toptopanma.com/%eb%82%98%ec%a3%bc%ec%98%a4%ed%94%bc%ea%b1%b8... Bristol-Myers Squibb Co. and Abbott Laboratories.

The drug industry has in the past defended its U.S. prices as a way to recoup hefty research and development costs.

The type of platinum found in the women's blood and urine was different than the traces of regular platinum not uncommon in people's bodies. It was a highly reactive platinum, used to help turn silicon oil into the honey-like gel that lends a more natural feel to a breast implant.

Concentrations were up to three times higher than in women who didn't have breast implants, according to findings by S.V.M. Maharaj, a chemist at American University. Maharaj was scheduled present the findings Thursday to the American Chemical Society in Philadelphia.

Ernest Lykissa, a forensic and clinical toxicologist who co-authored the paper, said the study's sample size was small. But Lykissa said it fairly represented hundreds of women with implants he's studied over the years.

Women who had implants the longest recorded the highest platinum concentrations. The heavy metal was also found in bone marrow, where blood cells are made.

Distinct from platinum released by catalytic converters in cars, platinum in implants is treated with nitric and hydrochloric acids and becomes very reactive, Lykissa said. The heavy metal readily binds in the human body, especially to nerve endings, short-circuiting communication with the brain.

"You see green, but you perceive a full moon," he said. "All of a sudden, your brain system is not working right."

Some women developed - http://www.stockhouse.com/search?searchtext=women%20developed nervous tics, had faulty perception, and impaired hearing - http://answers.yahoo.com/search/search_result?p=impaired%20hearing&submi... and eyesight, he said.

Children born to women with implants had problems with eyesight and hearing, too, but those nervous system disorders may have been caused by something else, he cautioned.

The Food and Drug Administration in January stunned plastic surgeons when, contradicting the advice of its expert panel, it rejected Inamed's bid to reintroduce silicone breast implants. After safety concerns rose, the FDA banned such implants in 1992 for most patients.

In January, the drug regulatory agency asked Inamed for more details about what happens when silicone seeps from the implant.

Dan Cohen, a spokesman for 보령출장마사지 - https://www.anmapop.com/%eb%b3%b4%eb%a0%b9%ec%b6%9c%ec%9e%a5%ec%83%b5%cf... Santa Barbara, Calif.-based Inamed, said the company would speak in detail about its formal reply, submitted to the FDA earlier this month.

But at the FDA's October 2003 advisory board meeting, the company briefly discussed platinum dispersion and concentration in implant patients. The company has tracked those patients for three years.

"It was not an issue that anyone dwelled on — either our presentation or the panel," Cohen said.

For its part, the FDA in 2002 surveyed scientific literature that indicated platinum leaks from implants into surrounding breast tissue. Researchers said they didn't find anything suggesting women had allergic responses to leached platinum.

Paul H. Wooley, director of research for orthopedic surgery at Wayne State University, said it's been suspected for at least a decade that heavy metals used in manufacturing might cause problems for women who receive implants.

"I'm not sure these questions have been answered because, in general, they haven't been asked," Wooley said. "For political reasons, working on breast-implant patients has been somewhat difficult to do."

By Diedtra Henderson